Global markets have entered a period of recalibration as the war between the U.S. and Iran ripples through one of the world’s most critical energy arteries. The disruption of oil and gas shipments through the Strait of Hormuz has tightened supply expectations and stirred fresh volatility across energy markets.
Investors, as they often do in uncertain times, have turned to history for guidance. In the aftermath of major oil supply shocks, select sectors tend to rise above the noise. Energy, consumer staples, healthcare, and utilities have consistently delivered returns exceeding 5% in the 12 months following such disruptions.
These sectors draw strength from necessity. When energy costs climb and economic momentum softens, demand for essential goods and services rarely wavers. The resilience often translates into steadier earnings and, in turn, stronger stock performance.
Within this framework, healthcare stands out as a quiet stabilizer. Against this backdrop, Boston Scientific Corporation (BSX) has emerged as one of the highest-rated names to watch, offering a potential hedge as markets navigate the crosscurrents of rising energy risk and economic uncertainty.
Based in Marlborough, Massachusetts, Boston Scientific designs and delivers medical devices across a wide spectrum of interventional specialties. The company addresses gastrointestinal, urological, neurological, cardiac, and vascular conditions through diagnostic tools, implants, and minimally invasive systems.
Holding a market cap of approximately $105.7 billion, it also extends its reach into cancer care and remote patient monitoring, reinforcing its role in critical healthcare delivery. BSX firmly sits in large-cap territory.
The stock has not escaped broader market pressure. Over the past 52 weeks, BSX stock has declined 28.19%, with a 27.47% drop over the last six months. Yet, recent momentum hints at a shift in tone, with the stock gaining 2.32% in the past five trading sessions.
From a valuation standpoint, BSX stock is trading at 20.20 times forward adjusted earnings and 4.74 times sales. The multiples exceed industry averages, yet they sit below the company’s own five-year average multiples, suggesting a favorable entry point for long-term investors.
